All you need to know about Biomarkers - Webinar

Please feel free to read, share your thoughts, your stories and connect with others!
JJH
Posts: 130
Joined: Mon Apr 24, 2017 7:26 am
Location: Europe

All you need to know about Biomarkers - Webinar

Postby JJH » Mon Sep 11, 2017 12:53 am


rp1954
Posts: 1174
Joined: Mon Jun 13, 2011 1:13 am

Re: All you need to know about Biomarkers - Webinar

Postby rp1954 » Mon Sep 11, 2017 6:43 pm

Thanks. I watched this after the webinar so I didn't get to ask any questions.
The post webinar link changed to here

This webinar leans toward PD-1 research,testing and education, and also recent genetic testing . He also noted that stage 1-3 patients with PD-1 indications may substantially benefit from 1-2 anti-PD1 treatments. He favorably noted the "liquid biopsy" tests in some situations now and a favorable future.

The webinar did have two important, cheap notes: First, that baby aspirin appears to have had a 90% reduction in recurrence in stage 1-3 patients who had PIK3CA mutations. Second, that right sided, Kras-wild CRC patients tended to flunk EGFR (erbitux, vectibix) treatment - right sided is cheap information. Nothing on common biomarkers like CA19-9 for KRAS, BRAF mutants, or targeting cheap drugs like cimetidine, celecoxib, and metformin.

He did acknowledge in the Q&A that biomarkers markedly change with time in metastatic cancer. My wife has had separate peaks in CEA, AFP and CA19-9 that had to be pounded down by multimodal attack. In the last six years, rises in CA19-9 and AFP mostly with changes in supplements and IV C, but prior credit to cimetidine, 5FU, and celecoxib. My wife's current CEA readings have been lower 2.x, near her postsurgical floor values on metronomic immunochemo, ca 1/6th - 1/9th of prior CEA peaks in the first 13 months.
Last edited by rp1954 on Mon Sep 11, 2017 6:50 pm, edited 2 times in total.
watchful, active caregiver for stage IVb CC since early 2010. immuno"Chemo forever," for mCRC

mpbser
Posts: 251
Joined: Wed Apr 19, 2017 11:52 am

Re: All you need to know about Biomarkers - Webinar

Postby mpbser » Mon Sep 11, 2017 6:49 pm

Thanks for posting this JJH and for the synopsis rp1954

I actually happened to be reviewing my husband's Oncopanel this evening and this came in very handy!
Wife 4/17 Dx age 45
5/17 - Lap left hemi
Adenocarcinoma
5 x 4 x 1 cm
low grade
T3 N2b M1a
Stage IV A
lymph nodes: 9 of 54
8/17 Sub-total colectomy
2nd tumor 5.5 cm width T1 N0
CEA: 1.4 Pre-op; 2.1 2 days Post-op
MSS/MSI-L
Lynch no; KRAS wild
Immunohistochemsistry: Normal expression of MLH1, MSH2, MSH6, and PMS2
Tumor DNA variants: MTOR, APC, TP53

NHMike
Posts: 326
Joined: Fri Jul 21, 2017 3:43 am

Re: All you need to know about Biomarkers - Webinar

Postby NHMike » Mon Sep 11, 2017 6:53 pm

rp1954 wrote:Thanks. I watched this after the webinar so I didn't get to ask any questions.
The post webinar link changed to here

This webinar leans toward PD-1 research,testing and education, and also recent genetic testing . He also noted that stage 1-3 patients with PD-1 indications may substantially benefit from 1-2 anti-PD1 treatments. He favorably noted the "liquid biopsy" tests in some situations now and a favorable future.

The webinar did have two important, cheap notes: First, that baby aspirin appears to have had a 90% reduction in recurrence in stage 1-3 patients who had PIK3CA mutations. Second, that right sided, Kras-wild CRC patients tended to flunk EGFR (erbitux, vectibix) treatment - right sided is cheap information. Nothing on common biomarkers like CA19-9 for KRAS, BRAF mutants, or targeting cheap drugs like cimetidine, celecoxib, and metformin.

He did acknowledge in the Q&A that biomarkers markedly change with time in metastatic cancer. My wife has had separate peaks in CEA, AFP and CA19-9 that had to be pounded down by multimodal attack. In the last six years, rises in CA19-9 and AFP mostly with changes in supplements and IV C, but prior credit to cimetidine, 5FU, and celecoxib. My wife's current CEA readings have been lower 2.x, near her postsurgical floor values on metronomic immunochemo, ca 1/6th - 1/9th of prior CEA peaks in the first 13 months.



Thanks for the summary.
Mike in NH:
Rectal Bleeding biopsy June 23, 2017, Diagnosed Stage 3B rectal cancer late July 2017 via MRI.
T3, N1b, M0.
Chemo (Xeloda) and radiation from 07/31/17 to 09/08/17.
CEA before treatment: 2.7. CEA after 14 treatments 1.9 to 1.8 after treatment.
KRAS Mutant KRAS p.Gly12Asp

SweetC80
Posts: 15
Joined: Fri Sep 01, 2017 1:28 pm

Re: All you need to know about Biomarkers - Webinar

Postby SweetC80 » Wed Sep 13, 2017 8:26 am

Sounds interesting and informative, thanks for posting.
My Mom's history
68 years old at diagnoses
12/16 Stage IIIb Rectal Cancer CEA 4.4
1/17-2/17 Chemoradiation
5/17 Colon (9 non resectable polyps), Rectum and Anus removal Perm Ileostomy Bag
7/17 Starts FOLFOX
9/17 Stage IV 9cm Liver Met plus abdominal Lymph Nods and suspicious Lung Nodule CEA 197
9/17 Start Irincotecan

mpbser
Posts: 251
Joined: Wed Apr 19, 2017 11:52 am

Re: All you need to know about Biomarkers - Webinar

Postby mpbser » Thu Sep 14, 2017 11:16 am

I just wish the presenter named the "better" biomarker detectable in blood tests that can be used to detect recurrence. I realize it's still in development, but I'd like to know what it is.
Wife 4/17 Dx age 45
5/17 - Lap left hemi
Adenocarcinoma
5 x 4 x 1 cm
low grade
T3 N2b M1a
Stage IV A
lymph nodes: 9 of 54
8/17 Sub-total colectomy
2nd tumor 5.5 cm width T1 N0
CEA: 1.4 Pre-op; 2.1 2 days Post-op
MSS/MSI-L
Lynch no; KRAS wild
Immunohistochemsistry: Normal expression of MLH1, MSH2, MSH6, and PMS2
Tumor DNA variants: MTOR, APC, TP53


Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: Bing [Bot], Google [Bot] and 45 guests